Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicentre, Open-Label, Umbrella Study of SCIB1 and iSCIB1+ in Patients With Advanced Unresectable Melanoma Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)

NCT04079166 is registered in ClinicalTrials.gov with Scancell Ltd as lead sponsor.

NCT NCT04079166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04079166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicentre, Open-Label, Umbrella Study of SCIB1 and iSCIB1+ in Patients With Advanced Unresectable Melanoma Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
Lead sponsor
Scancell Ltd
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 19, 2019
Completion date
January 31, 2027
Enrollment
173 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma, melanoma (skin), melanoma stage iii, melanoma stage iv